In this study, we investigate the mechanisms of MEK inhibitor primary and acquired resistance and determine whether other inhibitors, such as Akt and NF-κB inhibitor, can be used to overcome MEK inhibitor primary and acquired resistance in human colorectal cancer cells harboring KRAS, BRAF and PIK3CA mutation. The gene discussed is MAP2K7; the disease is colorectal cancer.